Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK

Journal of Medical Economics

Volumn 11, Issue 3, 2008, Pages 471-484

  Martin, Alan ^a   Cottrell, Suzanne ^b   Standaert, Baudouin ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b IQVIA   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Paediatric vaccination; Rotavirus; Utility

Indexed keywords

ACUTE DISEASE; ALGORITHM; ARTICLE; CHILD CARE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ECONOMIC EVALUATION; GASTROENTERITIS; HEALTH CARE UTILIZATION; HUMAN; ORAL REHYDRATION THERAPY; PATIENT MOBILITY; PEDIATRICIAN; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; ROTAVIRUS; SCORING SYSTEM; SELF CARE; UNITED KINGDOM; VIRUS INFECTION;

AGE FACTORS; CHILD, PRESCHOOL; GASTROENTERITIS; GREAT BRITAIN; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; PRIMARY HEALTH CARE; QUALITY OF LIFE; ROTAVIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 55049117203     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802321047     Document Type: Article

References (37)

1. Eliason BC, Lewan RB. Gastroenteritis in children: principles of diagnosis and treatment. American Family Physician 1998; 58: 1769-1776.
2. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scandinavian Journal of Infectious Diseases 1990; 22: 259-267.
3. Parashar UD, Hummelman EG, Bresee JS et al. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases 2003; 9: 565-572.
4. Parashar UD, Gibson CJ, Bresse JS et al. Rotavirus and severe childhood diarrhea. Emerging Infectious Diseases 2006; 12: 304-306.
5. Carlin JB, Chondros P, Masendycz P et al. Rotavirus infection and rates of hospitalisation for acute gastroenteritis in young children in Australia, 1993-1996. Medical Journal of Australia 1998; 169: 252-256.
6. Ryan MJ, Ramsay M, Brown D et al. Hospital admissions attributable to rotavirus infection in England and Wales. Journal of Infectious Diseases 1996; 174(Suppl. 1): S12-S18.
7. The Pediatric ROTavirus European CommitTee (PROTECT). The paediatric burden of rotavirus, disease in Europe. Epidemiology and Infection 2006; 134: 908-916.
8. Cunliffe NA, Allan C, Lowe SJ et al. Healthcare-associated rotavirus gastroenteritis in a large paediatric hospital in the UK. Journal of Hospital Infection 2007; 67: 240-244.
9. Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatric Infectious Disease Journal 2008; 27: S20-S27.
10. Djuretic T, Ramsay M, Gay N et al. An estimate of the proportion of diarrhoeal disease episodes seen by general practitioners attributable to rotavirus in children under 5 y of age in England and Wales. Acta Paediatrica Supplement 1999; 88: 38-41.
11. Withdrawal of rotavirus vaccine recommendation. MMWR Morbidity and Mortality Weekly Report 1999; 48: 1007.
12. Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370: 1757-1763.
13. Glass RI, Parashar UD. The promise of new rotavirus vaccines. New England Journal of Medicine 2006; 354: 75-77.
14. Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine 2006; 354: 23-33.
15. Rheingans RD, Heylen J, Giaquinto C. Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense? Pediatric Infectious Disease Journal 2006; 25: S48-S55.
16. National Institute for Health and Clinical Excellence: The Guidelines Manual. London: National Institute for Health and Clinical Excellence 2007.
17. Senecal M, Brisson M, Lebel M et al. Burden of rotavirus-associated gastroenteritis in Canadian families: a prospective community based study (abstract P99). Canadian Journal of Infectious Disease and Medical Microbiology 2006; 17: 383.
18. Huppertz HI, Forster J, Heininger U et al. The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clinical Pediatrics 2008; 47: 363-371.
19. Martin A, Cottrell S. Estimating utility in rotavirus gastroenteritis in children under five in the UK (abstract PIH19). Value in Health 2006; 9: A258.
20. Janse AJ, Sinnema G, Uiterwaal et al. Quality of life in chronic illness: perceptions of parents and paediatricians. Archives of Disease in Childhood 2005; 90: 486-491.
21. Prosser LA, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations. Pharmacoeconomics 2007; 25: 713-726.
22. Torrance GW, Furlong W, Feeny D et al. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics 1995; 7: 503-520.
23. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford: Oxford University Press, 2005; 137-211.
24. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72.
25. Dolan P. Modeling valuations for EuroQol health states. Medical Care 1997; 35: 1095-1108.
26. Armon K, Stephenson T, MacFaul R et al. An evidence and consensus based guideline for acute diarrhoea management. Archives of Disease in Childhood 2001; 85: 132-142.
27. Polanco-Marin G, Gonzalez-Losa MR, Rodriguez-Angulo E et al. Clinical manifestations of the rotavirus infection and his relation with the electropherotypes and serotypes detected during 1998 and 1999 in Merida, Yucatan, Mexico. Journal of Clinical Virology 2003; 27: 242-246.
28. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007; 25: 3971-3979.
29. Grange A, Bekker H, Noyes J et al. Adequacy of health-related quality of life measures in children under 5 years old: systematic review. Journal of Advanced Nursing 2007; 59: 197-220.
30. Solans M, Pane S, Estrada MD et al. Health-related quality of life measurement in children and adolescents: a systematic review of generic and disease-specific instruments. Value in Health 2007; 11(4): 742-764.
31. Lorgelly PK, Joshi D, Iturriza GM et al. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiology and Infection 2008; 136: 44-55.
32. Goossens LM, Standaert B, Hartwig N et al. The cost-utility of rotavirus vaccination with Rotarix-trade mark (RIX4414) in the Netherlands. Vaccine 2008; 26: 1118-1127.
33. Fruytier A, Van Schoor J, Standaert B. Vaccination with RIX4414 is cost-effective in a Belgian setting (abstract PIH3). Value in Health 2006; 9: A253.
34. Standaert B, Marocco A, Assael B et al. Analisi di costo-efficacia della vaccinazione universale in Italia con it vaccino Rix4414 contro i rotavirus. Pharmacoeconomics - Italian Research Articles 2008; 10: 23-35.
35. Martin A, Standaert B. Cost-effectiveness of infant vaccination with Rotarix(tm) in the UK (abstract 586). Presented at European Society for Paediatric Infectious Diseases (ESPID) 25th Annual Meeting, Porto, Portugal, 2-4 May, 2007.
36. Newall AT, Beutels P, Macartney K et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25: 8851-8860.
37. Constenla D, O'Ryan M, Navarrete MS et al. Evaluaciónde costo-efectividad de la vacuna anti-rotavirus en Chile [Potential cost-effectiveness of a rotavirus vaccine in Chile]. Revista Médica de Chile 2006; 134: 679-688.